论文部分内容阅读
格兰氏阴性菌,特别是绿脓杆菌的感染,在临床治疗上仍然是一个严重的问题。目前这方面还没有一个比较理想的临床药物。自从以氨苄青霉素为基本骨架进行化学改造以来,在抗阴性菌方面已有了一个较好的突破。这就是将氨苄青霉素的氨基进行酰化或改造成为α-脲的衍生物。这些衍生物在抗阴性菌方面,特别是在抗绿脓杆菌方面,大都有较好的活性。呋苄青霉素就是其中的一个。作为一个新化合物,最早是由 Brestol-Myer公司发表的。代号是 BL-P1597。结构式为:
Gram-negative bacteria, especially Pseudomonas aeruginosa infection, is still a serious problem in clinical treatment. At present, there is no ideal clinical drug in this aspect. Since the chemical modification of ampicillin as a basic skeleton, there has been a good breakthrough in anti-negative bacteria. This is the acylation or modification of the amino group of ampicillin to a derivative of α-urea. These derivatives are mostly active against anti-negative bacteria, especially against Pseudomonas aeruginosa. Fubicin is one of them. As a new compound, it was first published by Brestol-Myer. Code is BL-P1597. Structural formula is: